Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 30 of 228 for:    metformin and cancer AND Hypoglycemic

Metformin Hydrochloride vs. Placebo in Overweight or Obese Patients at Elevated Risk for Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01793948
Recruitment Status : Completed
First Posted : February 18, 2013
Last Update Posted : March 30, 2018
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Anna Maria Storniolo, Indiana University School of Medicine

Brief Summary:
This randomized clinical trial studies metformin hydrochloride in overweight or obese patients at elevated risk for breast cancer. Metformin hydrochloride may decrease the expression of early tumor makers in breast tissue of patients at increased risk for breast cancer

Condition or disease Intervention/treatment Phase
Breast Cancer Obesity Drug: metformin hydrochloride Other: placebo Other: laboratory biomarker analysis Early Phase 1

Detailed Description:

PRIMARY OBJECTIVES:

I. To determine the changes in the signal pathway profiling of breast tissue using reverse phase proteomics in tissue biopsy of overweight or obese women at elevated risk for breast cancer treated with metformin (metformin hydrochloride) (850mg orally twice a day) for 12 cycles.

SECONDARY OBJECTIVES:

I. To determine the effect of metformin on breast tissue density of overweight or obese women at elevated risk for breast cancer using qualitative mammographic fat density criteria.

II. To determine the effect of metformin on the insulin axis in serum of overweight or obese women at elevated risk for breast cancer treated with metformin (850mg orally twice a day) for 12 cycles.

III. To determine the toxicities associated with metformin.

OUTLINE: Patients are randomized to 1 of 2 treatment arms.

ARM I: Patients receive metformin hydrochloride by mouth once daily on days 1-30 in course 1 and twice daily on days 1-30 thereafter. Treatment repeats every 30 days for 12 courses in the absence of disease progression or unacceptable toxicity.

ARM II: Patients receive placebo by mouth once daily on days 1-30 in course 1 and twice daily on days 1-30 thereafter. Treatment repeats every 30 days for 12 courses in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 6 months for up to 5 years.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 24 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Prevention
Official Title: A Double Blind Prospective Study of Metformin vs. Placebo in Overweight or Obese Post-menopausal Women at Elevated Risk for Breast Cancer
Actual Study Start Date : April 16, 2013
Actual Primary Completion Date : January 9, 2018
Actual Study Completion Date : January 9, 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Arm Intervention/treatment
Experimental: Arm I (metformin hydrochloride)
Patients receive metformin hydrochloride by mouth once daily on days 1-30 in course 1 and twice daily on days 1-30 thereafter. Treatment repeats every 30 days for 12 courses in the absence of disease progression or unacceptable toxicity.
Drug: metformin hydrochloride
Given PO
Other Name: Glucophage

Other: laboratory biomarker analysis
Correlative studies

Placebo Comparator: Arm II (placebo)
Patients receive placebo by mouth once daily on days 1-30 in course 1 and twice daily on days 1-30 thereafter. Treatment repeats every 30 days for 12 courses in the absence of disease progression or unacceptable toxicity.
Other: placebo
Given PO
Other Name: PLCB

Other: laboratory biomarker analysis
Correlative studies




Primary Outcome Measures :
  1. Changes in the phosphorylation of proteins after metformin exposure [ Time Frame: Baseline and 12 months ]
    Reverse phase proteomic assays (RPPA) will be performed to measure changes in the phosphorylation of proteins after metformin exposure. Changes in the phosphorylation of proteins after metformin exposure will be calculated and compared using two-sample t-tests. As a supplemental analysis, analysis of covariance (ANCOVA) will be used to model the 12 month levels adjusted for baseline. Assumptions for analysis will be checked and non-parametric methods used if needed; however it is expected that the data will be normally distributed on the log scale.


Secondary Outcome Measures :
  1. Changes in ordinal level of breast density [ Time Frame: Baseline and 12 months ]
    Changes in ordinal level of breast density will be performed using the breast density criteria previously established by Boyd and colleagues (New England Journal of Medicine 2007). Each image will be grouped into one of six categories: 0%, <10%, 10-25%, 25-50%, 50-75% and >75%. Changes will be compared between the two groups using Wilcoxon Rank-Sum tests.

  2. Proportion of patients experiencing adverse events assessed using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 [ Time Frame: Up to 30 days ]
    Will be tabulated by arm and grade.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients must be post-menopausal women; post-menopausal women are defined as: (1) those >= 50 years of age who had not menstruated during the preceding 12 months or who had castrate follicle-stimulating hormone levels (> 40 IU/L), (2) those who had undergone a bilateral oophorectomy
  • Patients must be at elevated risk for breast cancer based on strong family history or a history of breast biopsy documenting atypical hyperplasia anytime in the past; for this study strong family history is defined as having:

    • 1 first-degree (parent, offspring, sibling) relative =< 50 years old when diagnosed with breast cancer, or
    • >= 2 first-degree relatives of any age when diagnosed with breast cancer, or
    • >= 2 second-degree (aunts, uncles, grandparents, grandchildren, nieces, nephews, or half-siblings) maternal or paternal relatives diagnosed with breast cancer and at least 1 diagnosed at =< 50 years of age
  • Patients must have a body mass index (BMI) >= 25.0 as calculated by the formula: weight in pounds / height squared x 703 = BMI; a BMI of:

    • 18.5-24.9 is considered normal;
    • 25.0-29.9 is considered overweight;
    • 30.0+ is regarded as obese
  • Patients must be willing to complete a bilateral mammogram at baseline with repeat exam after 12 cycles of protocol therapy; patients who have had a mammogram within 1 month prior to registration to protocol therapy will not need to repeat the exam
  • Patients must be willing to provide a core tissue biopsy at baseline and with repeat tissue collection after 12 cycles of protocol therapy
  • White blood cell (WBC) >= 3.0 x 109/L
  • Granulocytes (polymorphs + bands) >= 1.5 x 109/L
  • Platelets >= 100 x 109/L
  • Hemoglobin >= 110 g/L
  • Aspartate aminotransferase (AST) =< 1.8 X upper limit of normal (ULN)
  • Alanine aminotransferase (ALT) =< 1.8 X ULN
  • Alkaline phosphatase =< 2 X ULN
  • Serum creatinine =< 115 umol/L (1.3mg/dL)
  • Serum bilirubin =< institution ULN (except for subjects with Gilbert's Disease who are eligible despite elevated serum bilirubin level)
  • 12 hour fasting glucose level < 7.0 mmol/L
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 1 within 28 days of registration
  • Life expectancy of >= 5 years
  • Subjects must be accessible for treatment, adverse event tracking and follow-up as determined by the treating physician
  • Subject consent and authorization for the release of health information must be obtained according to local institutional guidelines

Exclusion Criteria:

  • No history of any malignancy except: adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, or other solid tumors curatively treated with no evidence of disease for >= 5 years
  • No known diabetes (type 1 or 2) or baseline fasting glucose >= 7.0 mmol/L
  • No known hypersensitivity or intolerance to metformin
  • No condition associated with increased risk of metformin-associated lactic acidosis (e.g. congestive heart failure defined as New York Heart Association [NYHA] class III or IV functional status, history of acidosis of any type; habitual intake of 3 or more alcoholic beverages per day)
  • No current treatment with metformin, sulfonylureas, thiazolidinediones or insulin for any reason
  • No breastfeeding
  • No concurrent or planned participation in randomized trials of weight loss or exercise interventions or trials targeting insulin, insulin-like growth factor 1 (IGF-1) or their receptors

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01793948


Locations
Layout table for location information
United States, Indiana
Indiana University Melvin and Bren Simon Cancer Center
Indianapolis, Indiana, United States, 46202
Sponsors and Collaborators
Anna Maria Storniolo
National Cancer Institute (NCI)
Investigators
Layout table for investigator information
Principal Investigator: Anna Maria Storniolo, MD Indiana University Melvin and Bren Simon Cancer Center

Layout table for additonal information
Responsible Party: Anna Maria Storniolo, Professor of Clinical Medicine, Indiana University School of Medicine
ClinicalTrials.gov Identifier: NCT01793948     History of Changes
Other Study ID Numbers: IUCRO-0365
NCI-2013-00422 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
1301010355 ( Other Identifier: Indiana University IRB )
First Posted: February 18, 2013    Key Record Dates
Last Update Posted: March 30, 2018
Last Verified: March 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Neoplasms
Metformin
Hypoglycemic Agents
Overweight
Breast Diseases
Skin Diseases
Body Weight
Signs and Symptoms
Physiological Effects of Drugs